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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe discovery of induced pluripotent stem cells (iPSCs) has created promising new avenues for therapies in regenerative medicine.
However, the tumorigenic potential of undifferentiated iPSCs is a major safety concern for clinical translation. To address this issue,
we demonstrated the efficacy of suicide gene therapy by introducing inducible caspase-9 (iC9) into iPSCs. Activationof iC9with a specific
chemical inducer of dimerization (CID) initiates a caspase cascade that eliminates iPSCs and tumors originated from iPSCs.We introduced
this iC9/CID safeguard system into a previously reported iPSC-derived, rejuvenated cytotoxic T lymphocyte (rejCTL) therapymodel and
confirmed that we can generate rejCTLs from iPSCs expressing high levels of iC9 without disturbing antigen-specific killing activity. iC9-
expressing rejCTLs exert antitumor effects in vivo. The systemefficiently and safely induces apoptosis in these rejCTLs. These results unite
to suggest that the iC9/CID safeguard system is a promising tool for future iPSC-mediated approaches to clinical therapy.INTRODUCTION
Human induced pluripotent stem cells (iPSCs) can unlimit-
edly self-renew and differentiate into various cell types (Ta-
kahashi et al., 2007). Their pluripotency makes iPSCs a
promising tool for therapy in a wide range of diseases at
present refractory to treatment (Inoue et al., 2014). Recent
studies, however, reported the tumorigenic potential of
contaminated undifferentiated iPSCs and the malignant
transformation of differentiated iPSCs (Lee et al., 2013a;
Nori et al., 2015). The tumorigenic risks of iPSCs could be
reduced by several strategies, such as sorting out undiffer-
entiated cells with antibodies targeting surface-displayed
biomarkers (Tang et al., 2011), killing undifferentiated cells
with cytotoxic antibodies (Choo et al., 2008), or elimina-
tion of remaining undifferentiated pluripotent cells with
chemical inhibitors (Ben-David et al., 2013; Lee et al.,
2013b). However, these strategies may not suffice to lower
risk to acceptable levels, because the tumorigenic risk of
iPSC-based cell therapy arises not just from contamination
with undifferentiated iPSCs but also from other unex-Stem Cellpected events associated with long-term culture for reprog-
ramming and redifferentiation. There is always a chance of
unexpected issues associated with first-in-human clinical
studies.
Because suicide systems can be designed not to evoke
cross-resistance to conventional agents, they can poten-
tiate therapy—efficiently inducing apoptosis in transduced
cells—without increasing toxicity. However, many suicide
systems have drawbacks, proving less clinically effective
than desired. HSV-TK, the gene encoding herpes simplex
virus thymidine kinase, with ganciclovir (GCV), for
example, is a well-known suicide gene system used as a
safety switch for adoptive T cell therapy or cancer treat-
ment (Ciceri et al., 2005, 2007). In fact, recent reports indi-
cate that the HSV-TK/GCV approach effectively removes
tumorigenic cells among murine iPSCs (Chen et al., 2013;
Lim et al., 2013). This system is nonetheless potentially
limited as a safeguard system, because HSV-TK targets
DNA synthesis in a cell-cycle-dependent manner and can
kill only fast-dividing cells. This may leave populations of
slowly dividing cells intact, with resistance to treatment.Reports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors 597
Cell killing may require many days and is usually incom-
plete, potentially delaying clinical benefit (Brenner et al.,
2013; Hoyos et al., 2012; Leen et al., 2014). Its prodrug,
GCV,may cause side effects such as renal dysfunction, liver
dysfunction, and pancytopenia. Moreover, because HSV-
TK is immunogenic, humoral immunity may reduce its
efficacy (Berger et al., 2006; Traversari et al., 2007).
On the other hand, inducible caspase-9 (iC9), encoded
by a suicide gene engineered from human caspase-9
(CASP9), is not immunogenic, and can kill transduced cells
in a cell-cycle-independent manner. iC9 is a fusion protein
engineered by replacing the caspase recruitment domain
(CARD) with a mutated FK506-binding protein (FKBP12)
to allow conditional dimerization (Straathof et al.,
2005b). In the presence of a chemical inducer of dimeriza-
tion (CID; AP1903 or its functionally identical analog
AP20187) (Clackson et al., 1998), dimerized iC9 directly ac-
tivates intracytoplasmic caspase-3, bypassing activation of
the mitochondrial apoptotic pathway, swiftly triggering
apoptosis in transduced cells (Di Stasi et al., 2011). In a clin-
ical study, infused iC9-transduced donor T cells underwent
rapid apoptosis after CID treatment, and graft-versus-host
disease (GVHD) symptoms receded dramatically without
relapse of leukemia (Di Stasi et al., 2011; Zhou et al.,
2014). iC9 is also a promising tool for cancer treatment,
because its mesenchymal stromal cell-based delivery may
effectively target non-small-cell lung cancer cells for elimi-
nation (Ando et al., 2014). Therefore, we decided to use iC9
to safeguard against problems during clinical and transla-
tional investigation of iPSC-based cell therapy.
We succeeded in generating iPSCs from antigen-specific
cytotoxic T lymphocytes (CTLs) in HIV1-infected patients
(Nishimura et al., 2013). These T cell-derived iPSCs
(T-iPSCs) were then redifferentiated into HIV1-specific
CTLs. CTLs continuously exposed to viral or tumor anti-
gens, with long-term expansion, may become exhausted
(Klebanoff et al., 2006; Wherry, 2011). Whereas fully ‘‘reju-
venated’’ CTLs (rejCTLs) derived from T-iPSCs have higher
proliferative capacity, younger memory phenotype, and
longer telomeres than the original patient-derived CTLs
(Nishimura et al., 2013), the actual in vivo efficacy of
rejCTLs has not been tested formally. Moreover, some engi-
neered Tcell immunotherapies incurred GVHD after donor
lymphocyte infusion, or ‘‘on-target, off-tumor toxicities’’
(Fedorov et al., 2013; Gargett and Brown, 2014) that might
also be seen with iPSC-derived T cell therapy. With clinical
trials in prospect, we explored the effectiveness and safety
of an iC9 safeguard systemusing these CTLs.Wehere docu-
ment that rejCTLs are effective against Epstein-Barr
virus (EBV)-induced tumors in vivo and that these rejCTLs
expressing iC9 can be eliminated by activation of this sys-
tem in vivo, showing that the iC9 safeguard system both is
practically useful and exhibits enhanced safety in the CTL598 Stem Cell Reports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Atherapy model. These results may facilitate broad applica-
tion of this safeguard system in other branches of iPSC-
derived regenerative medicine.
RESULTS
Activation of iC9 with CID Effectively Induces
Apoptosis in iPSCs
To assess the efficacy of suicide gene therapy based on an
iC9 system,we first cloned iC9 andmCherry into a lentiviral
vector carrying either Ubc or EF1a promoters (Figure 1A).
However, we could not obtain high titers of iC9-containing
lentivirus. We hypothesized that the effect of iC9 during
lentiviral packaging disturbed 293T cells with high-titer
lentivirus production. The caspase inhibitor qVD-Oph
completely blocks iC9-induced cell death (Ando et al.,
2014). We therefore added qVD-Oph to the medium to
protect 293T cells during lentivirus production. This
greatly enhanced lentivirus production (up to 3.91 3 102-
to 3.35 3 103-fold versus untreated cells; Figure S1A).
We established two T-iPSC lines for adoptive T cell
therapy from CTLs specific for either human immunodefi-
ciency virus 1 or Epstein-Barr virus (HIV1-iPS and EBV-iPS)
and transduced them with lentivirus-derived iC9. Ex-
pression of human pluripotency-associated genes in iC9-
iPSCs was comparable to that in non-transduced iPSCs
(NT-iPSCs) (Figure S1B). Pluripotency of iC9-iPSCs was
confirmed by teratoma formation (Brivanlou et al., 2003).
Six weeks after intratestis or subcutaneous injection of
iC9-iPSCs into nonobese diabetic severe combined immu-
nodeficient (NOD-Scid) mice, teratomas containing all
three germ layers had formed (Figure S1C).
To evaluate the efficacy of this iC9 system in inducing
apoptosis, binding of annexin V phycoerythrin (‘‘annexin
V’’) and uptake of 7-amino-actinomycin D (7-AAD) by
iC9-iPSCs were quantified by flow cytometry 24 hr after
addition of CID. Over 95% of Ubc-iC9-transduced iPSCs
(EBV-iPS: 94.43% ± 3.00%; HIV1-iPS: 95.0% ± 5.54%)
and over 75% of EF1a-iC9-transduced iPSCs (EBV-iPS:
77.88% ± 11.17%; HIV1-iPS: 72.19% ± 11.99%) underwent
apoptosis; in controls lacking the iC9 system, 10%–15%
underwent apoptosis (Figure S1D). Ubc-iC9 induced
apoptosis in iPSCs more powerfully than EF1a-iC9 (p =
0.0007, EBV-iPS; p < 0.0001, HIV1-iPS; two-way ANOVA).
In addition, after sorting several times for iC9/mCherry
expression, silencing of Ubc-iC9 was not so clearly seen
as was silencing of EF1a-iC9. We therefore decided mainly
to use Ubc-iC9-iPSCs in this study. Because proportional
iC9-induced cell death varied among lung cancer cell lines
(Ando et al., 2014), we compared apoptosis rates among
four iPSC lines transduced with Ubc-iC9. All four lines
exhibited equally high sensitivity (>95%) to this iC9/CID
system (Figure 1B). Moreover, iC9-EBV-iPSCs lost theiruthors
Figure 1. iC9 Activation with CID Induces
Robust Apoptosis of iPSCs
(A) Schematic representation of two lenti-
viral iC9 bicistronic vectors containing Ubc
or EF1a promoters. Both vectors contain the
suicide gene iC9, cleavable 2A-like
sequence, and mCherry as a selectable
marker.
(B) T-iPSC lines (EBV-iPSC and HIV1-iPSC)
and cell lines TKDA3-4 and TKCBSeV9 were
transduced with lentiviral Ubc-iC9. These
established four Ubc-iC9-iPSC lines and four
nontransduced iPSC lines were treated with
CID (80 nM), and apoptosis was measured
24 hr later by flow cytometry for annexin
V/7-AAD marking. Data are representative
of three independent triplicate experi-
ments. Error bars represent ± SD. ****p <
0.0001 by two-way ANOVA. ns, not signifi-
cant.
(C) NT-EBV-iPSCs and iC9-EBV-iPSCs were
plated; on the following day, both iPSCs
were left untreated or were treated with
CID. On days 1, 3, and 7 after CID treatment,
iPSCs in each dish were stained with meth-
ylene blue. Data are representative of three
independent experiments.
See also Figure S1.ability to form colonies for 7 days after treatment with CID
(Figure 1C), and even after 14 days (data not shown). On
the other hand, NT-EBV-iPSC colony formation was not
affected (Figure 1C). These results suggest that activation
of iC9 effectively induces apoptosis in iPSCs in vitro.
The iC9-CID System Can Debulk iPSC-Derived
Teratomas
To examine the effects of CID treatment on established
tumors, we injected 1.3 3 106 iC9-iPSCs (iC9-EBV-iPS or
iC9-HIV1-iPS) or NT-iPSCs (NT-EBV-iPS or NT-HIV1-iPS)
into testes of NOD-Scidmice andmonitored tumor volume
(TV) once a week. All host mice except for two mice (NT-
EBV-iPS, n = 8; iC9-EBV-iPS, n = 12; NT-HIV1-iPS, n = 8;
iC9-HIV1-iPS, n = 8) developed bilateral intratesticular
tumors. On day 29, average TVs were 334.45 ±
122.30 mm3 (NT-EBV-iPS), 483.07 ± 191.88 mm3 (iC9-
EBV-iPS), 674.79 ± 394.68 mm3 (NT-HIV1-iPS), and
589.81 ± 263.16 mm3 (iC9-HIV1-iPS). The host mice
received intraperitoneally injected CID (Figure 2A, left),
50 mg/mouse, for 3 successive days (day 30 to day 32).
TVs were again determined on day 36. Tumors shrank
dramatically only in mice carrying iC9-iPSC-derivedStem Celltumors, and not in mice that received iPSCs without
the iC9 system. The tumor size ratio was calculated as
(TVday 36  TVday 0)/(TVday 29  TVday 0). We could not
measure tumor size long term because many mice died,
which we ascribe to failure to tolerate invasive weekly
operations to permit testis measurement. In addition, his-
topathologic study required that some mice be sacrificed.
However, regrowth of the tumors was not observed in
surviving mice on day 45 (NT-EBV-iPS, n = 4; iC9-EBV-
iPS, n = 4; NT-HIV1-iPS, n = 4; iC9-HIV1-iPS, n = 7) (Fig-
ure 2A, left). The ratio averaged 0.3 in mice injected with
iC9-EBV-iPSCs and treated with CID. Because these testes
included cystic cavities and because testes themselves
grow as their owners grow, tumor size ratios in this group
did not reach zero. However, they averaged 1.2 in mice in-
jected with iC9-iPSCs and not treated with CID (p = 0.0005
by two-way ANOVA) and 1.6 in mice injected with NT-
iPSCs and treated with CID (p = 0.0001 by two-way
ANOVA) (Figure 2A, right). Similar results were also ob-
tained in mice injected with iC9-HIV1-iPSCs (Figure 2A).
Histopathologic examination of the tumors revealed a
typical pattern of testicular teratoma in the untreated
mice (Figure 2B, upper), whereas the testes of mice injectedReports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors 599
Figure 2. iC9 Can Debulk Teratomas
Originated from iPSCs
(A) NT-iPSCs or iC9-iPSCs were injected into
the testes of NOD-Scid mice (day 0). Around
day 30, mice were divided into four groups
(EBV-iPS: NT without CID [n = 4], NT with
CID [n = 3], iC9 without CID [n = 6], and iC9
with CID [n = 6]; HIV1-iPS: NT without CID
[n = 4], NT with CID [n = 3], iC9 without CID
[n = 4], and iC9 with CID [n = 4]) with or
without daily intraperitoneal injections of
CID. The average tumor volume in each
group from day 0 to day 45 is shown (left).
Error bars represent ± SEM. **p < 0.01 and
***p < 0.001 by two-way ANOVA. Using TVs
on days 0, 29, and 36, the tumor size ratio
was calculated (right). *p < 0.05, **p <
0.01, and ***p < 0.001 by two-way ANOVA.
(B) Tumors formed by iC9-HIV1-iPSCs in
testes of male NOD-Scid mice were untreated
or treated by CID (left). Representative H&E-
stained sections of intratesticular tumors of
untreated or CID-treated mice (middle). The
scale bars represent 1 mm. A high-magnifi-
cation view of the testis of a CID-treated
mouse (right). Hematoxylinophilic debris
marks cell loss ascribed to CID-induced
apoptosis. The scale bar represents 100 mm.with iC9-iPSCs and treated with CID contained multiple
cystic cavities with intramural nuclear debris, residua of
apoptosis (Figure 2B, lower). All these findings suggest
that the iC9-CID system can drastically reduce iPSC-
derived teratomas by inducing apoptosis.
High Expression of iC9 Neither Inhibits
Redifferentiation into rejCTLs nor Affects Their
Antigen Specificity and Killing Function
To address the effectiveness and safety of the iC9 safeguard
system in virus-specific rejCTLs, we generated hematopoi-
etic progenitor cells from iC9-iPSCs cultured on
C3H10T1/2 feeder cells in the presence of vascular endo-
thelial growth factor (VEGF) (Nishimura et al., 2013; Ta-
kayama et al., 2008). On day 14 of culture, iPSC-derived
sacs were extracted. They contained many hematopoietic
progenitor cell candidates (Figure 3A). On the following
day, flow cytometry analysis of these cells confirmed that600 Stem Cell Reports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors85% of CD235a, CD34+, and CD43+
cells expressed iC9/mCherry (Fig-
ure 3A). To induce T cell differentia-
tion, we transferred these cells onto
NOTCH ligand-expressing C3H10T1/
2 feeder cells (Timmermans et al.,2009) in the presence of Fms-related tyrosine kinase 3
ligand (FLT-3L), stem cell factor (SCF), and interleukin 7
(IL-7) (Nishimura et al., 2013). After 28 days of culture,
T lineage cells were harvested, mixed with irradiated
peripheral blood mononuclear cells (PBMCs), and stimu-
lated with IL-7, IL-15, and phytohemagglutinin.
Finally, we generated rejuvenated EBV-specificCTLs from
NT- and iC9-EBV-iPSCs (rejT-NT-EBV and rejT-iC9-EBV).
More than 95% of rejT-NT-EBV and rejT-iC9-EBV bound
to multimers of their respective target major histocompat-
ibility complex-viral peptide complex; these CTLs also
expressed CD8. Similarly, rejuvenated HIV1-specific
CTLs from NT- and iC9-HIV1-iPSCs were successfully
generated (rejT-NT-HIV1 and rejT-iC9-HIV1). rejT-iC9-
EBV and rejT-iC9-HIV1 expressed high levels of iC9, with
95% and 99%, respectively, expressing iC9/mCherry (Fig-
ure 3B). To determine whether these redifferentiated cells
expressed cytotoxicity-related molecules, we compared
Figure 3. iC9-iPSCs Can Efficiently
Differentiate into Virus-Specific CTLs
(A) iC9-HIV1-iPSC sacs on day 14 of culture
on C3H10T1/2 feeder cells (upper). The
scale bar represents 500 mm. One day after
sac extraction, extracted hematopoietic
progenitor cells were analyzed by flow cy-
tometry. Flow cytometric analysis of iC9/
mCherry expression by CD235a, CD34+, and
CD43+ gated cells (lower).
(B) Flow cytometric analysis of peptide-HLA
multimer labeling/CD8 expression by iPSC-
derived CTLs 14 days after the third stimu-
lation. Expression of iC9/mCherry by these
CTLs is shown. The plots are representative
of at least five independent differentiation
experiments.
(C) Quantitative PCR analysis to compare
the expression of cell-lysis molecules in PB
CD8+ T cells, original EBV-CTLs, rejT-NT-EBV,
and rejT-iC9-EBV (left). The same analysis
was also carried out in PB CD8+ T cells, rejT-
NT-HIV1, and rejT-iC9-HIV1 (right). Indi-
vidual PCR results were normalized against
18S rRNA. Data are presented as the mean of
three independent experiments ± SD.
(D) IFN-g production by original EBV-CTLs,
rejT-NT-EBV, and rejT-iC9-EBV in the pres-
ence of LMP2 peptide was measured using
ELISPOT. IFN-g production by original
HIV1-CTLs, rejT-NT-HIV1, and rejT-iC9-HIV1
in the presence of Nef peptide was measured
similarly. Data are presented as the mean ±
SD and are representative of three inde-
pendent triplicate experiments.
(E) In vitro 51Cr-release assay of original EBV-
CTLs, rejT-NT-EBV, and rejT-iC9-EBV (effec-
tors) and EBV-transformed B lymphoblastoid cell lines (targets) (upper) and that of rejT-NT-HIV1 and rejT-iC9-HIV1 (effectors) and Nef-pre-
senting LCLs (targets) (lower). Data are presented as themean± SD and are representative of at least three independent triplicate experiments.
See also Figure S2.gene expression profiles for rejT-iC9-EBV and rejT-iC9-
HIV1 with those for other cell lineages, including the orig-
inal EBV-CTL, rejT-NT-EBV, rejT-NT-HIV1, and PB CD8+
T cells. rejT-iC9-EBV and rejT-iC9-HIV1 showed cytotoxic
potential, with expression of GZMB, FASLG, and PRF1 (Fig-
ure 3C). The expression profiles for these CTLs were similar
to those for the original EBV-CTL and PB CD8+ T cells.
Because chimeric antigen receptor-expressing T cells
from iPSCs expressed only CD8a and very few cells ex-
pressed low amounts of CD8b (Themeli et al., 2013), we
also examined the expression of CD8a and CD8b in re-
jT-iC9-EBV and rejT-iC9-HIV1. It should be noted that
most of these iPSC-derived CTLs also expressed CD8a
(95.8% and 87.7%, respectively), whereas only 3% ex-
pressed CD8b (Figure S2).Stem CellWe next determined the specificity of EBV-CTLs and
HIV1-CTLs with interferon (IFN) g enzyme-linked immu-
nospot (ELISPOT) assays after stimulation with LMP2 or
Nef peptides, respectively. Our results indicated that the
original EBV-CTL clone, rejT-NT-EBV, and rejT-iC9-EBV
showed specific activity against LMP2 (respectively, 310 ±
26, 231 ± 13, and 227 ± 24 IFN-g spot-forming cells
[SFCs]/1,000). Similarly, all three HIV1-CTLs (original
HIV1-CTL clone, rejT-NT-HIV1, and rejT-iC9-HIV1) were
activated by Nef (respectively, 109 ± 34, 149 ± 60, and
197 ± 10 IFN-g SFCs/1,000) (Figure 3D) and showed strong
antigen-specific cytotoxicitywith respect toNef-presenting
cells. Poor proliferation capacity precluded cytotoxicity as-
saysusing theoriginalHIV1-CTLclone.At aneffector:target
(E:T) ratio of 40:1, rejT-iC9-HIV1 and rejT-NT-HIV1 killedReports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors 601
Figure 4. In Vivo Antitumor Effect of
iC9-iPSC-Derived EBV-CTLs
(A) NOD-Scid mice were inoculated intraper-
itoneally with HLA-A*02-positive EBV-LCL
cells labeled with GFP/FFluc and then treated
either with control or EBV-CTL lines. Mice
were divided into three groups that around
5 days later received rejT-iC9-EBV (n = 7),
rejT-NT-EBV (n = 5), or original EBV-CTLs (n =
5). ‘‘No treatment’’ indicates that mice were
injected with EBV-LCLs but not with CTLs (n =
4). Images of three representative mice from
each group are shown.
(B) Total body flux (photons/s) for each
mouse was quantified, and group averages
were calculated. Error bars represent ± SEM.
*p < 0.05 by one-way ANOVA comparing no
treatment to rejT-iC9-EBV, rejT-NT-EBV, or
original EBV-CTLs.
(C) Total tumor growth by day 21 after CTL
infusions is represented as log10 signal
change. Error bars represent ± SD. ****p <
0.0001 and ***p < 0.001 by one-way ANOVA.
(D) Kaplan-Meier survival curves for treated
and control mice (rejT-iC9-EBV, n = 7; rejT-
NT-EBV, n = 5; original EBV-CTLs, n = 5; no
treatment, n = 4). **p < 0.01 and *p < 0.05 by
the Gehan-Breslow-Wilcoxon test.Nef peptide-expressing target cells (49.1% and 52.2% spe-
cific 51Cr release, respectively), with minimal recognition
of control target cells pulsed with irrelevant peptides
(3.9% and 1.3% specific 51Cr release, respectively). On
the other hand, cytotoxicity of rejT-iC9-EBV, rejT-NT-EBV,
and even the original EBV-CTL clone with respect to
LMP2-presenting cells was relatively weak. At an E:T ratio
of 40:1, the original EBV-CTL clone, rejT-iC9-EBV, and
rejT-NT-EBV killed histocompatibility leukocyte antigen
(HLA) class I-matched target cells (17%,7.4%, and6.7%spe-
cific 51Cr release, respectively),withminimal recognitionof
HLA class I-mismatched control target cells (0.6%, 1.2%,
and 0.2% specific 51Cr release, respectively) (Figure 3E).
Our results demonstrated that rejCTLs derived from iC9-
iPSCs are virus specific and exhibit cytotoxic activity
against virus-infected cells. High expression of iC9 thus602 Stem Cell Reports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authorsneither inhibits redifferentiation into
rejCTLs nor affects antigen specificity
and killing function.
Safety and Effectiveness of iC9-
iPSC-Derived CTLs for Tumor
Therapy In Vivo
To elucidate whether iC9-iPSC-
derived CTL therapy is safe andrejT-iC9-EBVexerts antitumor effects in vivo, EBV lympho-
blastoid cell lines (EBV-LCLs) transduced with lentiviral
vector encoding a GFP-firefly luciferase fusion protein
(GFP/FFLuc) (3 3 106 cells/mouse) were intraperitoneally
engrafted into NOD-Scid mice. Light emission was moni-
tored as an indicator of tumor growth. Once biolumines-
cence occurred and progressively increased (around
5 days after tumor inoculation), mice were divided into
four groups. In the control group, no treatment was given
(n = 4); the others were treated with rejT-iC9-EBV (n = 7),
rejT-NT-EBV (n = 5), or original EBV-CTLs (n = 5) (10 3
106 per dose, three doses) followed by intraperitoneal injec-
tion of recombinant human IL-2, 1,000 U/mouse, three
times a week (Quintarelli et al., 2007; Vera et al., 2009).
As shown by bioluminescent imaging (Figures 4A–4C), tu-
mor signals declined as expected in mice treated with
original EBV-CTLs (0.41-fold, range 0.009–1.12). rejT-iC9-
EBV or rejT-NT-EBV also suppressed tumor signals as well
as or better than original EBV-CTLs (0.06-fold, range
0.009–0.13, rejT-iC9-EBV; 0.097-fold, range 0.012–0.32,
rejT-NT-EBV) (Figure 4C), yielding a survival advantage in
the group treatedwith rejT-iC9-EBV compared to the group
treated with original EBV-CTLs (p = 0.04) (Figure 4D). Tu-
mor signals regressed further in the groups treated with
rejT-iC9-EBV or rejT-NT-EBV than in the untreated group
(rejT-iC9-EBV, p < 0.0001; rejT-NT-EBV, p < 0.0001; original
EBV-CTLs, p = 0.0001; one-way ANOVA) (Figure 4C), and
resulted in a significant survival advantage compared to
tumor-bearing mice in the untreated group (p = 0.0039,
rejT-iC9-EBV; p = 0.0047, rejT-NT-EBV) (Figure 4D). Biolu-
minescence imaging additionally revealed that signaling
fell off more rapidly in mice treated with rejT-iC9-EBV
than in mice treated with rejT-NT-EBV (Figure 4B). In
contrast, signaling progressively increased in mice without
treatment (8.998-fold, range 3.99–16.3). These results sug-
gest that iC9-iPSC-derived CTLs are safe and effective for
tumor therapy in vivo and provide a survival benefit in
tumor-bearing mice.
Induction of Apoptosis in iC9-iPSC-Derived CTLs by a
Cascade of Caspase Activation In Vitro and In Vivo
To gain further insights into the effectiveness of the iC9
safeguard system, rejT-iC9-EBV and rejT-iC9-HIV1 were
treated with CID. Annexin V binding and 7-AAD uptake
were examined 24 hr later. Our results clearly demonstrated
that CID induces apoptosis in iC9-iPSC-derived CTLs (rejT-
iC9-HIV1, 96.81% ± 1.84%; rejT-iC9-EBV, 75.7% ± 2.0%)
that is robust compared with that in untreated CTLs
(rejT-iC9-HIV1, 17.03% ± 1.01%; rejT-iC9-EBV, 28.13% ±
0.91%; Figure 5A). In contrast, apoptosis was not increased
in CTLs without the iC9 safeguard system (original
EBV-CTL, rejT-NT-EBV, and rejT-NT-HIV1). To examine
the effects of CID on caspase activation, apoptosis-related
gene expression profiles were obtained for rejT-iC9-HIV1
and rejT-iC9-EBV 24 hr after CID treatment (although
treatment meant that such cells were few) and were
compared with similar profiles in cells without CID treat-
ment. CASP9 was upregulated 5.9 ± 3.24-fold in rejT-iC9-
HIV1 and 9.3 ± 1.9-fold in rejT-iC9-EBV 24 hr after CID
treatment. Because caspase-9 activation induces the activa-
tion of caspase-3, the effector caspase, we also assessed
CASP3 expression. CASP3 expression slightly decreased
(1.01 ± 0.26-fold) in rejT-iC9-HIV1 but increased 3.43 ±
0.84-fold in rejT-iC9-EBV 24 hr after CID addition. Interest-
ingly, expression of XIAP, an inhibitor of apoptosis, was
higher in rejT-iC9-EBV (6.5 ± 0.12-fold) than in rejT-iC9-
HIV1 (1.91-fold) (Figure S3). The difference inXIAP expres-
sion between rejT-iC9-EBV and rejT-iC9-HIV1 likely affects
sensitivity to iC9.Stem CellWe finally assessed the efficacy of the iC9 safeguard sys-
tem in vivo using an iC9-iPSC-derived CTL therapy model
(Figure 5B). The iC9/CID safeguard system was also effec-
tive in vivo. EBV-LCLs (53 106 cells/mouse) were intraper-
itoneally engrafted into NOD-Scid mice and treated with
GFP/FFluc-labeled rejT-iC9-EBV cells on day 0 (10 3 106
cells/mouse). Infused rejT-iC9-EBV cells localized and
could be tracked by bioluminescence imaging (Figure 5B).
Bioluminescent T cell signaling declined after injection of
CID (n = 4), whereas the signal persisted in control mice
without CID treatment (n = 3) on day 6 (p = 0.015 by un-
paired Student’s t test [two-tailed]; Figures 5B and 5C).
Additionally, EBV-LCLs (3 3 106 cells/mouse) were intra-
peritoneally engrafted into NOD-Scid mice and, after tu-
mor establishment (day 7 to day 5), mice were treated
with rejT-iC9-EBV cells (days 0 and 7). Flow cytometry
was used to monitor mCherry expression in peripheral
blood. Soon after mCherry-expressing CTLs could be de-
tected (around day 8), the mice received intraperitoneally
injected CID (50 mg/mouse) or PBS for 3 successive days
(n = 4 each) (day 9 to day 11). Twenty-four hours after
the last dose of CID, rejT-iC9-EBV cells could not be de-
tected in CID-treated mice (0.6% ± 0.4%) (Figure 5D),
whereas rejT-iC9-EBV cells were present in control mice
(8.25% ± 4.0%; p = 0.01 by unpaired Student’s t test)
(data not shown); this held true even 6 days after treat-
ment. These results collectively led us to conclude that
the iC9/CID safeguard system leads by a cascade of caspase
activation to efficient apoptosis in iC9-iPSC-derived CTLs
in vitro and in vivo, and that it will be a useful tool against
acute GVHD or cytokine release syndrome following cell
therapy and to limit ‘‘on-target, off-tumor toxicities’’ seen
in some engineered T cell immunotherapy.DISCUSSION
Our studies highlight the potential clinical significance of
the iC9 safeguard system. Recent studies introducing sui-
cide gene-based safeguard systems into mouse or rhesus
iPSCs report that teratoma formation was significantly de-
layed or inhibited only when treatment started before im-
plantation or soon after iPSC injection (Chen et al., 2013;
Lim et al., 2013; Wu et al., 2014; Zhong et al., 2011). In
our study, this was not so for CID treatment; when started
30 days after iC9-iPSC implantation, it caused dramatic
teratoma regression. These results indicate that our lentivi-
ral iC9/CID safeguard system may be useful practically.
Looking toward the introduction of the iC9/CID safe-
guard system to clinical use, we applied this system to
iPSC-derived (rejuvenated) CTL therapy to show how this
system could actually work. Our results indicated that
introduction of iC9 into iPSCs does not interfere with theirReports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors 603
Figure 5. Induction of Apoptosis in iC9-
iPSC-Derived CTLs by Activation of iC9
(A) Flow cytometric analysis of annexin V
binding and 7-AAD uptake by rejT-NT-HIV1
and rejT-iC9-HIV1 24 hr after CID treatment
(left). Original EBV-CTLs, rejT-NT-EBV, rejT-
iC9-EBV, rejT-NT-HIV1, and rejT-iC9-HIV1
were left untreated or treated with CID.
Apoptosis was assessed 24 hr after treat-
ment. Data are representative of three in-
dependent triplicate experiments. Error bars
represent ± SD. ****p < 0.0001 by two-way
ANOVA.
(B) In vivo bioluminescent imaging of rejT-
iC9-EBV expressing FFluc. NOD-Scid mice
inoculated intraperitoneally with EBV-LCL
cells and with rejT-iC9-EBV cells received
three doses of CID (50 mg) intraperitoneally
(n = 4). Comparison mice received no CID
(n = 3). Images of three representative mice
from each group are shown.
(C) FFluc signal intensities after rejT-iC9-
EBV cell transfer in each group. Error bars
represent ± SEM. *p < 0.05 by unpaired
Student’s t test (two-tailed).
(D) Study schema of in vivo rejT-iC9-
mCherry detection in peripheral blood (up-
per). mCherry expression was quantified by
flow cytometry (n = 4 per group). Repre-
sentative data of three experiments are
shown (lower).
(E) Schematic illustration of the iC9/CID
safeguard system to protect patients
receiving iPSC-derived CTL therapy.
See also Figure S3.pluripotency and differentiation ability. iC9-iPSCs could
efficiently differentiate into virus-specific CTLs that ex-
hibited continuously high iC9/mCherry expression.
These iC9-iPSC-derived CTLs could be eliminated by CID
treatment in vivo. EF1a-iC9 expression in rhesus iPSCs
reportedly is downregulated during in vitro and in vivo dif-
ferentiation due to DNA methylation within the promoter
(Wu et al., 2014). We initially compared the percentages of
apoptosis between Ubc-iC9-iPSCs and EF1a-iC9-iPSCs
24 hr after CID treatment. CID could induce apoptosis
more strongly in Ubc-iC9-iPSCs than in EF1a-iC9-iPSCs.
Ubc-iC9 expression levels were still high during and after
differentiation into virus-specific CTLs, and CID also
induced robust apoptosis of Ubc-iC9-iPSC-derived CTLs.
These data suggest that the Ubc promoter provides stable
expression of the iC9 transgene after iC9/mCherry sorting604 Stem Cell Reports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Aand is suitable for iPSC-derived cell therapy. To increase the
efficacy of this iC9 system further, iC9-transduced iPSCs
could be cloned and selected for maximum sensitivity for
CID and a minimum number of mutations in the genome.
Most of these CTLs do not express CD8b. Despite rela-
tively weak cytotoxicity for LMP2 antigen in vitro and
their unconventional phenotype (CD8a+, CD8b), these
rejT-iC9-CTLs exerted a significant antitumor effect in
mouse xenograft models. These rejCTLs may kill the target
cells using nonconventional, natural killer (NK)-like killing
mechanisms. This in vivo antitumor effect of rejT-iC9-CTLs
is encouraging that adoptive T cell therapy using rejT-iC9-
CTLs targeting tumors will be clinically feasible, especially
EBV-associated tumors such as Hodgkin’s disease, nasal NK
cell lymphoma, nasopharyngeal carcinoma, and EBV-asso-
ciated posttransplantation lymphoproliferative disease.uthors
If increased efficiency of this iC9/CID system is required,
the proteasome inhibitor bortezomib can be used. Bortezo-
mib and iC9/CID are strongly synergistic, enhancing
apoptosis in lung cancer cells by blocking the degradation
of active caspase-3 and caspase-9 (Ando et al., 2014). Of in-
terest in this regard is that the E3 ubiquitin ligase XIAP, an
inhibitor of apoptosis, binds to caspase-3 and targets it for
proteasomal degradation (Albeck et al., 2008; Huang et al.,
2001; Suzuki et al., 2001). Knockdown of XIAP enhances
iC9-induced apoptosis, suggesting that bortezomib maxi-
mizes iC9-induced apoptosis (Ando et al., 2014). Given
that bortezomib downregulates nuclear factor kB (Hide-
shima et al., 2009), which is a transcriptional target of
XIAP (Stehlik et al., 1998), bortezomib likely downregu-
lates XIAP expression.
As far as we know, tumor formation in a clinical study us-
ing lentivirus vectors has not been reported. However, in
clinical studies, to examine integration sites of lentivirus-
iC9 and choose clones most likely to be safe appears pru-
dent. An alternative approach may be to insert the iC9
system into a ‘‘safe harbor’’ site, such as AAVS1 or ROSA26,
through homologous recombination using highly efficient
new genetic manipulation technologies involving zinc-
finger nucleases (Hockemeyer et al., 2009), transcription
activator-like effector nucleases (Boch and Bonas, 2010),
or clustered regularly interspaced short palindromic repeats
(Cong et al., 2013; Jinek et al., 2013; Mali et al., 2013).
Our concept of the iC9/CID safeguard system for
iPSC-derived cell therapy can be presented as a schema (Fig-
ure 5E). This safeguard system can eliminate contami-
nating iPSCs, debulk tumors originated from iPSCs, stop
cytokine release syndrome associated with iPSC-derived
CTL therapy, and control ‘‘on-target, off-tumor toxicities’’.
It should be applicable to other cell therapies using iPSC-
derived cells. The iC9 safeguard system can be an efficient
and reliable approach to provide safety for future regenera-
tive therapy and first-in-human cell therapy.EXPERIMENTAL PROCEDURES
Vector Construction and Virus Production
A retrovirus vector encoding iC9 was purchased from Addgene
(pMSCV-F-del Casp9.IRES.GFP; 15567). Two iC9-expressing lenti-
viral vectors (Ubc-iC9 and EF1a-iC9) were generated from CS-
CDF-CG-PRE (Yamaguchi et al., 2012). Additional details are
provided in Supplemental Experimental Procedures.Generation of iC9-iPSCs
The institutional regulation board for human ethics at the Institute
ofMedical Science,University of Tokyo approved the experimental
protocol. PBMCs of an HLA-A*02:01-positive healthy donor were
used to generate an LMP2-specific CTL clone (Burrows et al.,
1995). This clone was specific for the LMP2 peptide FLYALALLLStem Cellthat is presented by HLA-A*02:01 (Lautscham et al., 2003). EBV-
iPS was established from this clone after informed consent was ob-
tained. HIV1-iPS is a previously established T-iPSC line from a
Nef138-8 (wild-type; WT)-specific CTL line derived from an HLA-
A24-positive patient chronically infected with HIV1 (Kawana-
Tachikawa et al., 2002; Nishimura et al., 2013). To introduce
lentivirus-derived iC9 into iPSCs, 1 3 105 iPSCs were plated on
24-well plates coated with Corning Matrigel Matrix and cultured
in Essential 8 medium (GIBCO, Life Technology) for 24 hr. iPSCs
were then transduced with lentiviral iC9 at anMOI of 20; medium
was replaced with freshmedium 6 hr after transduction. iC9-trans-
duced iPSCs were further cultured and iC9/mCherry-expressing
cells were sorted by flow cytometry (FACSAria II; BD Biosciences).
Additional details are provided in Supplemental Experimental
Procedures.
T Cell Differentiation from T-iPSCs
To differentiate human iPSCs into hematopoietic cells, we slightly
modified a published protocol (Nishimura et al., 2013; Takayama
et al., 2008). Details are provided in Supplemental Experimental
Procedures.
Measurement of Apoptosis
CID/AP20187 was purchased from Clontech as a B/B homodimer-
izer. Cells that bound annexin Vor took up 7-AADwere quantified
by flow cytometry (FACSAria II; BD Biosciences) using FlowJo soft-
ware (Tree Star). Details are provided in Supplemental Experi-
mental Procedures.
Teratoma Formation and In Vivo CID Treatment
Animal care was accorded with the guidance of The University of
Tokyo for animal and recombinant DNA experiments. The Animal
Care and Use Committee, Institute of Medical Science, University
of Tokyo approved all procedures. iC9-iPSCs and NT-iPSCs (1.3 3
106 cells) suspended in Corning Matrigel Matrix containing the
Rock inhibitor Y-27632 (10 mM) were injected into the testicular
interstitium of NOD-Scid mice. Tumor growth was monitored by
measuring testis size in three dimensions once a week. Thirty
days after injection, CID administration (50 mg intraperitoneally
daily for 3 successive days) was begun. Tumors with TV
<150 mm3 on day 29 were excluded from analysis. Using TVs on
days 0, 29, and 36, the tumor size ratio was calculated as (TVday 36
 TVday 0)/(TVday 29  Tvday 0). Thirty-five days after injection, the
mice were sacrificed and tumors were assessed as described above.
Antitumor Activity in In Vivo Model
To evaluate the antitumor effects of rejT-iC9-CTLs, HLA class
I-matched EBV-LCLs transduced with a lentiviral vector encoding
GFP/FFluc were sorted for GFP expression by flow cytometry.
NOD-Scid mice were engrafted intraperitoneally with EBV-LCLs
(3 3 106 cells/mouse) and tumor growth was monitored using a
bioluminescence system. Once a progressive increase of biolumi-
nescence occurred, usually 5 days after tumor inoculation, mice
were treated intraperitoneally with three once-weekly doses of
rejT-iC9-EBV, rejT-NT-EBV, or original EBV-CTLs (10 3 106 CTLs/
mouse). The mice treated with EBV-CTLs received IL-2 (1,000 U)
intraperitoneally three times a week (Vera et al., 2009). OneReports j Vol. 5 j 597–608 j October 13, 2015 j ª2015 The Authors 605
additional control group received only tumor cells. Tumor burden
was monitored by the Xenogen IVIS imaging system. Mice were
injected intraperitoneally with D-luciferin (150 mg/kg), and
light output was analyzed using Xenogen Living Image software
version 2.50. The intensity of the signal was measured as total
photon/s/cm2/steradian (p/s/cm2/sr).
In Vivo Elimination of iC9-iPSC-Derived CTLs
To examine whether iC9-iPSC-derived CTLs can be eliminated by
this iC9/CID safeguard system in vivo, NOD-Scid mice were en-
grafted intraperitoneally with EBV-LCLs (5 3 106 cells/mouse)
and received 10 3 106 rejT-iC9-EBV cells labeled with GFP/FFluc
on day 0.Mice were treated with CID (50 mg intraperitoneally daily
for 3 successive days (day 2 to day 4). Comparisonmice received no
CID. Mice were imaged as described above.
Detection of iC9-iPSC-Derived CTLs In Vivo
NOD-Scid mice inoculated intraperitoneally with HLA-A*02-posi-
tive EBV-LCL cells labeled with GFP/FFluc were treated with 10 3
106 rejT-iC9-EBV cells on day 0 and day 7. After rejT-iC9-EBV cells
were detected in peripheral blood (around 8 days after the first rejT-
iC9-EBV administration), the mice received intraperitoneally in-
jected CID, 50 mg/mouse, for 3 successive days. Control mice
received three doses of PBS. Flow cytometry of peripheral blood
was used to identify rejT-iC9-EBV cells (expressing mCherry).
Statistics
All data are presented as mean ± SD or SEM as stated in the figure
legends. Results were analyzed by ANOVA or unpaired Student’s
t test (two-tailed) as stated in the text. Comparison of survival
curveswas done using theGehan-Breslow-Wilcoxon test. All statis-
tical analyses were performed using Excel (Microsoft) and Prism
(GraphPad Software) programs. Values of p <0.05 were considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and three figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2015.07.011.
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